James Costello
Concepts (405)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Urinary Bladder Neoplasms | 11 | 2023 | 196 | 2.290 |
Why?
| Gene Expression Profiling | 9 | 2023 | 1518 | 1.430 |
Why?
| Algorithms | 13 | 2018 | 1467 | 1.320 |
Why?
| Antineoplastic Agents | 7 | 2020 | 1879 | 1.010 |
Why?
| Computational Biology | 9 | 2018 | 530 | 0.930 |
Why?
| Transcriptome | 7 | 2023 | 725 | 0.920 |
Why?
| Biomarkers, Tumor | 5 | 2022 | 1040 | 0.920 |
Why?
| Gene Regulatory Networks | 6 | 2023 | 228 | 0.910 |
Why?
| Cell Line, Tumor | 18 | 2023 | 2710 | 0.870 |
Why?
| Drug Resistance, Neoplasm | 6 | 2021 | 636 | 0.840 |
Why?
| Neoplasms | 8 | 2020 | 2097 | 0.830 |
Why?
| Prostatic Neoplasms | 4 | 2023 | 921 | 0.820 |
Why?
| Crowdsourcing | 5 | 2023 | 14 | 0.790 |
Why?
| Computer Simulation | 5 | 2018 | 872 | 0.780 |
Why?
| Premature Birth | 2 | 2023 | 276 | 0.770 |
Why?
| Cell-Free Nucleic Acids | 1 | 2021 | 26 | 0.740 |
Why?
| Cisplatin | 2 | 2018 | 262 | 0.690 |
Why?
| Blood Proteins | 1 | 2021 | 231 | 0.650 |
Why?
| Pre-Eclampsia | 1 | 2021 | 165 | 0.650 |
Why?
| Gene Expression Regulation, Neoplastic | 12 | 2023 | 1141 | 0.640 |
Why?
| MutS Homolog 2 Protein | 1 | 2018 | 12 | 0.640 |
Why?
| Chromosomes, Human | 1 | 2018 | 39 | 0.620 |
Why?
| Pharmaceutical Preparations | 1 | 2020 | 165 | 0.620 |
Why?
| Gestational Age | 1 | 2021 | 760 | 0.610 |
Why?
| Whole Genome Sequencing | 1 | 2018 | 94 | 0.610 |
Why?
| Fluorescence | 1 | 2018 | 148 | 0.600 |
Why?
| Transcription Factors | 4 | 2022 | 1528 | 0.600 |
Why?
| CRISPR-Cas Systems | 1 | 2018 | 78 | 0.600 |
Why?
| Models, Biological | 4 | 2018 | 1620 | 0.580 |
Why?
| Tripartite Motif Proteins | 1 | 2017 | 30 | 0.580 |
Why?
| Breast Neoplasms | 5 | 2021 | 1862 | 0.570 |
Why?
| Metabolic Networks and Pathways | 1 | 2018 | 168 | 0.570 |
Why?
| Genetic Loci | 1 | 2018 | 262 | 0.560 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 1355 | 0.550 |
Why?
| Homeodomain Proteins | 5 | 2023 | 463 | 0.540 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2017 | 139 | 0.540 |
Why?
| Genomics | 6 | 2023 | 635 | 0.500 |
Why?
| Telomerase | 4 | 2020 | 206 | 0.480 |
Why?
| Image Processing, Computer-Assisted | 1 | 2018 | 683 | 0.460 |
Why?
| MAP Kinase Kinase Kinases | 3 | 2021 | 68 | 0.460 |
Why?
| DNA-Binding Proteins | 6 | 2022 | 1314 | 0.420 |
Why?
| Competitive Behavior | 1 | 2013 | 39 | 0.420 |
Why?
| Oligonucleotide Array Sequence Analysis | 7 | 2016 | 740 | 0.400 |
Why?
| Receptors, Androgen | 3 | 2021 | 131 | 0.400 |
Why?
| Cooperative Behavior | 2 | 2016 | 381 | 0.380 |
Why?
| Humans | 55 | 2023 | 114654 | 0.380 |
Why?
| Carcinoma, Transitional Cell | 3 | 2017 | 53 | 0.380 |
Why?
| Biomedical Research | 2 | 2016 | 585 | 0.370 |
Why?
| Rhabdomyosarcoma | 2 | 2022 | 54 | 0.360 |
Why?
| Drosophila | 3 | 2008 | 133 | 0.360 |
Why?
| Lung Neoplasms | 3 | 2018 | 2177 | 0.340 |
Why?
| Mutation | 7 | 2023 | 3345 | 0.340 |
Why?
| Carcinoma, Pancreatic Ductal | 2 | 2023 | 211 | 0.340 |
Why?
| Zebrafish Proteins | 2 | 2022 | 246 | 0.330 |
Why?
| Protein Interaction Mapping | 1 | 2009 | 101 | 0.320 |
Why?
| Protein Tyrosine Phosphatases | 2 | 2020 | 147 | 0.300 |
Why?
| Drosophila melanogaster | 1 | 2009 | 191 | 0.290 |
Why?
| Databases, Genetic | 3 | 2018 | 206 | 0.290 |
Why?
| DNA Helicases | 2 | 2021 | 133 | 0.280 |
Why?
| Prostatic Neoplasms, Castration-Resistant | 2 | 2017 | 40 | 0.280 |
Why?
| Triple Negative Breast Neoplasms | 2 | 2019 | 157 | 0.260 |
Why?
| Neoplasm Metastasis | 5 | 2020 | 523 | 0.260 |
Why?
| Animals | 27 | 2023 | 31698 | 0.250 |
Why?
| Pancreatic Neoplasms | 2 | 2023 | 731 | 0.250 |
Why?
| Promoter Regions, Genetic | 6 | 2021 | 1131 | 0.250 |
Why?
| Epigenesis, Genetic | 3 | 2020 | 520 | 0.250 |
Why?
| Oncogene Proteins, Fusion | 3 | 2023 | 179 | 0.250 |
Why?
| Epithelial-Mesenchymal Transition | 3 | 2021 | 167 | 0.240 |
Why?
| Meta-Analysis as Topic | 2 | 2023 | 158 | 0.240 |
Why?
| Proteomics | 3 | 2021 | 836 | 0.220 |
Why?
| Nuclear Proteins | 2 | 2020 | 591 | 0.210 |
Why?
| Datasets as Topic | 1 | 2023 | 99 | 0.210 |
Why?
| Mice | 17 | 2023 | 14863 | 0.210 |
Why?
| Sarcoma, Ewing | 1 | 2023 | 64 | 0.200 |
Why?
| Melanoma | 2 | 2023 | 620 | 0.200 |
Why?
| MDS1 and EVI1 Complex Locus Protein | 1 | 2022 | 6 | 0.200 |
Why?
| Neoplasm Invasiveness | 3 | 2018 | 442 | 0.200 |
Why?
| ROC Curve | 2 | 2021 | 442 | 0.190 |
Why?
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2021 | 5 | 0.190 |
Why?
| Cell Proliferation | 8 | 2021 | 2186 | 0.190 |
Why?
| Muscle Development | 1 | 2022 | 98 | 0.190 |
Why?
| Proto-Oncogene Proteins B-raf | 1 | 2023 | 192 | 0.190 |
Why?
| ADAM10 Protein | 1 | 2021 | 28 | 0.180 |
Why?
| Asymptomatic Diseases | 1 | 2021 | 75 | 0.180 |
Why?
| Tumor Microenvironment | 2 | 2020 | 430 | 0.180 |
Why?
| Receptors, CCR2 | 1 | 2020 | 28 | 0.180 |
Why?
| Gamma Rays | 1 | 2021 | 48 | 0.180 |
Why?
| Carcinoma, Lobular | 1 | 2021 | 44 | 0.180 |
Why?
| Radiosurgery | 1 | 2023 | 299 | 0.180 |
Why?
| Gene Ontology | 1 | 2020 | 46 | 0.180 |
Why?
| PAX3 Transcription Factor | 1 | 2020 | 11 | 0.180 |
Why?
| Proto-Oncogene Protein c-ets-1 | 1 | 2020 | 18 | 0.180 |
Why?
| Neoplasm Recurrence, Local | 3 | 2023 | 858 | 0.180 |
Why?
| Forkhead Box Protein O1 | 1 | 2020 | 15 | 0.180 |
Why?
| Cytoreduction Surgical Procedures | 1 | 2020 | 38 | 0.180 |
Why?
| Wnt Signaling Pathway | 1 | 2022 | 146 | 0.180 |
Why?
| Amyloid Precursor Protein Secretases | 1 | 2021 | 72 | 0.180 |
Why?
| CD8-Positive T-Lymphocytes | 3 | 2020 | 687 | 0.170 |
Why?
| Jumonji Domain-Containing Histone Demethylases | 1 | 2020 | 59 | 0.170 |
Why?
| Radiation Injuries | 1 | 2021 | 128 | 0.170 |
Why?
| Chromosomes, Human, Pair 21 | 1 | 2019 | 31 | 0.170 |
Why?
| Cell Differentiation | 3 | 2022 | 1700 | 0.170 |
Why?
| Receptors, Interferon | 1 | 2019 | 47 | 0.170 |
Why?
| Homologous Recombination | 1 | 2019 | 20 | 0.170 |
Why?
| Small Molecule Libraries | 1 | 2020 | 79 | 0.170 |
Why?
| Chemotherapy, Adjuvant | 1 | 2020 | 332 | 0.160 |
Why?
| Prognosis | 7 | 2021 | 3327 | 0.160 |
Why?
| Discoidin Domain Receptor 2 | 1 | 2019 | 2 | 0.160 |
Why?
| Female | 19 | 2023 | 59488 | 0.160 |
Why?
| RNA Interference | 1 | 2021 | 433 | 0.160 |
Why?
| Trisomy | 1 | 2019 | 68 | 0.160 |
Why?
| Kynurenine | 1 | 2019 | 81 | 0.160 |
Why?
| Reproducibility of Results | 2 | 2023 | 2762 | 0.160 |
Why?
| Machine Learning | 2 | 2022 | 316 | 0.160 |
Why?
| Dasatinib | 1 | 2019 | 46 | 0.160 |
Why?
| Microbiota | 2 | 2023 | 647 | 0.160 |
Why?
| Fibrosis | 1 | 2021 | 453 | 0.160 |
Why?
| Neoadjuvant Therapy | 1 | 2020 | 304 | 0.150 |
Why?
| SOXB1 Transcription Factors | 1 | 2019 | 60 | 0.150 |
Why?
| Receptors, Estrogen | 1 | 2021 | 372 | 0.150 |
Why?
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2020 | 172 | 0.150 |
Why?
| Neoplasm Proteins | 2 | 2018 | 384 | 0.150 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 367 | 0.150 |
Why?
| Chloroquine | 1 | 2018 | 52 | 0.150 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 2 | 2023 | 113 | 0.150 |
Why?
| Molecular Conformation | 1 | 2018 | 135 | 0.150 |
Why?
| Macrolides | 1 | 2018 | 56 | 0.150 |
Why?
| Neoplasms, Experimental | 1 | 2019 | 151 | 0.150 |
Why?
| Lysosomes | 1 | 2018 | 123 | 0.150 |
Why?
| Signal Transduction | 6 | 2021 | 4512 | 0.150 |
Why?
| Monte Carlo Method | 1 | 2018 | 138 | 0.150 |
Why?
| Histone Code | 1 | 2017 | 28 | 0.150 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 386 | 0.140 |
Why?
| Down Syndrome | 2 | 2019 | 335 | 0.140 |
Why?
| Probability | 1 | 2018 | 289 | 0.140 |
Why?
| Cell Cycle Proteins | 1 | 2021 | 551 | 0.140 |
Why?
| Adenocarcinoma | 1 | 2023 | 795 | 0.140 |
Why?
| Immunity, Cellular | 1 | 2019 | 248 | 0.140 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2019 | 193 | 0.140 |
Why?
| Cell Death | 1 | 2018 | 322 | 0.140 |
Why?
| DNA Damage | 1 | 2019 | 351 | 0.140 |
Why?
| Data Interpretation, Statistical | 2 | 2009 | 321 | 0.140 |
Why?
| Cadherins | 2 | 2015 | 175 | 0.140 |
Why?
| B7-H1 Antigen | 1 | 2018 | 139 | 0.140 |
Why?
| Histidine Kinase | 1 | 2016 | 33 | 0.140 |
Why?
| CD24 Antigen | 1 | 2016 | 20 | 0.130 |
Why?
| DNA Methylation | 2 | 2017 | 495 | 0.130 |
Why?
| Nomograms | 1 | 2016 | 41 | 0.130 |
Why?
| Sulfonamides | 1 | 2020 | 445 | 0.130 |
Why?
| YY1 Transcription Factor | 1 | 2016 | 27 | 0.130 |
Why?
| Transcriptional Activation | 1 | 2018 | 337 | 0.130 |
Why?
| Urologic Neoplasms | 1 | 2016 | 25 | 0.130 |
Why?
| Drug Delivery Systems | 1 | 2019 | 296 | 0.130 |
Why?
| Deoxycytidine | 1 | 2017 | 138 | 0.130 |
Why?
| Organizational Innovation | 2 | 2016 | 132 | 0.130 |
Why?
| Ovarian Neoplasms | 1 | 2020 | 388 | 0.130 |
Why?
| Adenosine Triphosphatases | 1 | 2016 | 153 | 0.130 |
Why?
| Genetic Heterogeneity | 1 | 2015 | 48 | 0.120 |
Why?
| Bayes Theorem | 3 | 2023 | 329 | 0.120 |
Why?
| Neoplastic Stem Cells | 1 | 2019 | 329 | 0.120 |
Why?
| Survival Rate | 4 | 2021 | 1644 | 0.120 |
Why?
| rho Guanine Nucleotide Dissociation Inhibitor beta | 1 | 2014 | 4 | 0.120 |
Why?
| Up-Regulation | 1 | 2018 | 807 | 0.120 |
Why?
| Nerve Tissue Proteins | 1 | 2019 | 529 | 0.120 |
Why?
| Immunotherapy | 1 | 2019 | 474 | 0.120 |
Why?
| Alleles | 1 | 2017 | 789 | 0.120 |
Why?
| Telomere Homeostasis | 1 | 2015 | 24 | 0.120 |
Why?
| Membrane Proteins | 1 | 2021 | 1018 | 0.120 |
Why?
| Transcription, Genetic | 3 | 2017 | 1313 | 0.120 |
Why?
| Longitudinal Studies | 1 | 2021 | 2387 | 0.120 |
Why?
| Histone Demethylases | 1 | 2014 | 28 | 0.120 |
Why?
| Phenotype | 2 | 2020 | 2796 | 0.120 |
Why?
| Ubiquitin Thiolesterase | 1 | 2014 | 35 | 0.120 |
Why?
| Infant, Newborn | 2 | 2023 | 5044 | 0.120 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2018 | 615 | 0.120 |
Why?
| rho GTP-Binding Proteins | 1 | 2014 | 61 | 0.120 |
Why?
| Phylogeny | 3 | 2023 | 789 | 0.120 |
Why?
| Ornithine Decarboxylase Inhibitors | 1 | 2013 | 3 | 0.110 |
Why?
| Microsatellite Repeats | 1 | 2014 | 136 | 0.110 |
Why?
| Drug Synergism | 1 | 2014 | 316 | 0.110 |
Why?
| Anabolic Agents | 1 | 2013 | 11 | 0.110 |
Why?
| Arthritis, Rheumatoid | 1 | 2022 | 1003 | 0.110 |
Why?
| High-Throughput Screening Assays | 1 | 2015 | 123 | 0.110 |
Why?
| Models, Theoretical | 1 | 2017 | 515 | 0.110 |
Why?
| Gene Expression Regulation, Developmental | 2 | 2022 | 800 | 0.110 |
Why?
| International Cooperation | 1 | 2014 | 171 | 0.110 |
Why?
| Drug Combinations | 1 | 2014 | 287 | 0.110 |
Why?
| Databases, Protein | 2 | 2014 | 59 | 0.110 |
Why?
| Organ Sparing Treatments | 1 | 2013 | 31 | 0.110 |
Why?
| Brain Neoplasms | 1 | 2021 | 979 | 0.110 |
Why?
| Models, Molecular | 1 | 2018 | 1369 | 0.110 |
Why?
| Epigenomics | 1 | 2014 | 101 | 0.110 |
Why?
| Leukemia, Myeloid, Acute | 1 | 2020 | 534 | 0.110 |
Why?
| Biomarkers | 2 | 2021 | 3408 | 0.110 |
Why?
| Xenograft Model Antitumor Assays | 3 | 2021 | 698 | 0.110 |
Why?
| Pregnancy | 2 | 2023 | 5517 | 0.110 |
Why?
| Models, Statistical | 1 | 2016 | 599 | 0.100 |
Why?
| Cluster Analysis | 2 | 2016 | 455 | 0.100 |
Why?
| Software | 2 | 2014 | 530 | 0.100 |
Why?
| Prostate | 1 | 2013 | 156 | 0.100 |
Why?
| Superoxides | 1 | 2013 | 214 | 0.100 |
Why?
| Cyclin-Dependent Kinase 4 | 1 | 2012 | 33 | 0.100 |
Why?
| Integrins | 2 | 2023 | 79 | 0.100 |
Why?
| Community-Institutional Relations | 1 | 2013 | 89 | 0.100 |
Why?
| Genome-Wide Association Study | 1 | 2018 | 1177 | 0.100 |
Why?
| Tumor Suppressor Proteins | 1 | 2014 | 282 | 0.100 |
Why?
| Apoptosis | 3 | 2021 | 2362 | 0.100 |
Why?
| Mice, Inbred C57BL | 5 | 2021 | 4692 | 0.100 |
Why?
| Alternative Splicing | 1 | 2013 | 187 | 0.100 |
Why?
| B-Lymphocytes | 2 | 2014 | 766 | 0.100 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 228 | 0.100 |
Why?
| Saccharomyces cerevisiae | 3 | 2012 | 476 | 0.100 |
Why?
| Genome, Insect | 2 | 2009 | 22 | 0.090 |
Why?
| Male | 10 | 2023 | 55579 | 0.090 |
Why?
| Reactive Oxygen Species | 1 | 2013 | 531 | 0.090 |
Why?
| MCF-7 Cells | 2 | 2021 | 105 | 0.090 |
Why?
| Genetic Predisposition to Disease | 1 | 2018 | 2085 | 0.090 |
Why?
| Enzyme Inhibitors | 1 | 2013 | 750 | 0.090 |
Why?
| Hematopoietic Stem Cells | 1 | 2013 | 343 | 0.090 |
Why?
| Testosterone | 1 | 2013 | 343 | 0.090 |
Why?
| Gene Expression Regulation, Bacterial | 1 | 2012 | 285 | 0.090 |
Why?
| Inflammation | 1 | 2020 | 2478 | 0.090 |
Why?
| Horns | 1 | 2009 | 1 | 0.090 |
Why?
| Expressed Sequence Tags | 1 | 2009 | 38 | 0.090 |
Why?
| Pseudogenes | 1 | 2009 | 18 | 0.080 |
Why?
| Coleoptera | 1 | 2009 | 24 | 0.080 |
Why?
| Drug Discovery | 2 | 2022 | 123 | 0.080 |
Why?
| Systems Integration | 1 | 2009 | 37 | 0.080 |
Why?
| Models, Genetic | 2 | 2009 | 562 | 0.080 |
Why?
| Stem Cells | 1 | 2013 | 545 | 0.080 |
Why?
| Genes, Fungal | 1 | 2009 | 49 | 0.080 |
Why?
| Zebrafish | 2 | 2022 | 411 | 0.080 |
Why?
| Tumor Cells, Cultured | 2 | 2021 | 849 | 0.080 |
Why?
| Genetic Diseases, Inborn | 1 | 2008 | 36 | 0.070 |
Why?
| Genes, Insect | 1 | 2007 | 20 | 0.070 |
Why?
| Gene Deletion | 1 | 2009 | 356 | 0.070 |
Why?
| Mitochondria | 1 | 2013 | 747 | 0.070 |
Why?
| Combined Modality Therapy | 2 | 2020 | 1121 | 0.070 |
Why?
| Genome, Human | 1 | 2009 | 347 | 0.070 |
Why?
| BRCA1 Protein | 2 | 2020 | 56 | 0.070 |
Why?
| Disease | 1 | 2008 | 85 | 0.070 |
Why?
| Genetics, Population | 1 | 2008 | 188 | 0.070 |
Why?
| Oxidative Stress | 1 | 2013 | 1076 | 0.070 |
Why?
| Selection, Genetic | 1 | 2008 | 242 | 0.070 |
Why?
| Prednisone | 2 | 2017 | 229 | 0.070 |
Why?
| Chromatin | 2 | 2022 | 428 | 0.060 |
Why?
| Follow-Up Studies | 3 | 2020 | 4411 | 0.060 |
Why?
| T-Lymphocytes | 1 | 2013 | 1737 | 0.060 |
Why?
| Cell Line | 3 | 2019 | 2635 | 0.060 |
Why?
| Adult | 3 | 2021 | 30542 | 0.060 |
Why?
| Base Sequence | 3 | 2017 | 2114 | 0.060 |
Why?
| Anti-Bacterial Agents | 1 | 2013 | 1481 | 0.060 |
Why?
| Cell Movement | 2 | 2021 | 868 | 0.060 |
Why?
| Evolution, Molecular | 1 | 2007 | 430 | 0.060 |
Why?
| Protein Binding | 2 | 2020 | 1889 | 0.050 |
Why?
| Proto-Oncogene Protein c-fli-1 | 1 | 2023 | 17 | 0.050 |
Why?
| RNA-Binding Protein EWS | 1 | 2023 | 17 | 0.050 |
Why?
| BCG Vaccine | 1 | 2023 | 18 | 0.050 |
Why?
| Internet | 1 | 2008 | 596 | 0.050 |
Why?
| Cells, Cultured | 3 | 2016 | 3885 | 0.050 |
Why?
| Mice, Nude | 2 | 2016 | 630 | 0.050 |
Why?
| Biological Assay | 1 | 2023 | 112 | 0.050 |
Why?
| Proteins | 1 | 2008 | 908 | 0.050 |
Why?
| Myogenin | 1 | 2022 | 11 | 0.050 |
Why?
| Vagina | 1 | 2023 | 146 | 0.050 |
Why?
| MyoD Protein | 1 | 2022 | 27 | 0.050 |
Why?
| Rhabdomyosarcoma, Embryonal | 1 | 2022 | 16 | 0.050 |
Why?
| Adjuvants, Immunologic | 1 | 2023 | 206 | 0.050 |
Why?
| Mice, Knockout | 2 | 2022 | 2568 | 0.050 |
Why?
| Aged | 4 | 2023 | 19068 | 0.050 |
Why?
| Regulatory Sequences, Nucleic Acid | 1 | 2022 | 81 | 0.050 |
Why?
| Cell Lineage | 2 | 2013 | 309 | 0.050 |
Why?
| Chondrogenesis | 1 | 2022 | 79 | 0.050 |
Why?
| Chromatin Assembly and Disassembly | 1 | 2022 | 88 | 0.050 |
Why?
| Phenylthiohydantoin | 1 | 2021 | 40 | 0.050 |
Why?
| Skull | 1 | 2022 | 119 | 0.050 |
Why?
| Ephrin-B2 | 1 | 2021 | 36 | 0.050 |
Why?
| Wnt Proteins | 1 | 2022 | 134 | 0.050 |
Why?
| Neural Crest | 1 | 2022 | 117 | 0.050 |
Why?
| Breast | 1 | 2021 | 139 | 0.040 |
Why?
| Nitriles | 1 | 2021 | 149 | 0.040 |
Why?
| Benzamides | 1 | 2021 | 169 | 0.040 |
Why?
| Cartilage | 1 | 2022 | 182 | 0.040 |
Why?
| Tamoxifen | 1 | 2021 | 191 | 0.040 |
Why?
| Melanoma, Experimental | 1 | 2020 | 89 | 0.040 |
Why?
| beta Catenin | 1 | 2022 | 219 | 0.040 |
Why?
| Quinolinic Acid | 1 | 2019 | 7 | 0.040 |
Why?
| Chromatin Immunoprecipitation | 1 | 2020 | 128 | 0.040 |
Why?
| Biosynthetic Pathways | 1 | 2019 | 19 | 0.040 |
Why?
| Chondrocytes | 1 | 2022 | 199 | 0.040 |
Why?
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 44 | 0.040 |
Why?
| Androgens | 1 | 2021 | 167 | 0.040 |
Why?
| Double-Blind Method | 1 | 2023 | 1660 | 0.040 |
Why?
| Enhancer Elements, Genetic | 1 | 2020 | 151 | 0.040 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2020 | 157 | 0.040 |
Why?
| Nanog Homeobox Protein | 1 | 2019 | 11 | 0.040 |
Why?
| Inhibitor of Differentiation Proteins | 1 | 2018 | 2 | 0.040 |
Why?
| Cell Cycle | 1 | 2021 | 542 | 0.040 |
Why?
| Mice, SCID | 1 | 2019 | 314 | 0.040 |
Why?
| Enhancer of Zeste Homolog 2 Protein | 1 | 2017 | 37 | 0.040 |
Why?
| 5-Methylcytosine | 1 | 2017 | 16 | 0.040 |
Why?
| Kaplan-Meier Estimate | 1 | 2020 | 811 | 0.040 |
Why?
| Sequence Analysis, RNA | 1 | 2020 | 385 | 0.040 |
Why?
| CpG Islands | 1 | 2017 | 117 | 0.040 |
Why?
| Protein Kinase Inhibitors | 1 | 2023 | 785 | 0.040 |
Why?
| Mice, Inbred NOD | 1 | 2019 | 555 | 0.030 |
Why?
| Polycomb Repressive Complex 2 | 1 | 2017 | 59 | 0.030 |
Why?
| Co-Repressor Proteins | 1 | 2016 | 13 | 0.030 |
Why?
| Taxoids | 1 | 2016 | 93 | 0.030 |
Why?
| Chromosomes, Human, Pair 9 | 1 | 2016 | 43 | 0.030 |
Why?
| Logistic Models | 1 | 2021 | 1840 | 0.030 |
Why?
| Mice, Inbred BALB C | 1 | 2019 | 1143 | 0.030 |
Why?
| Chromosome Deletion | 1 | 2016 | 95 | 0.030 |
Why?
| Immunoprecipitation | 1 | 2016 | 151 | 0.030 |
Why?
| Heterografts | 1 | 2016 | 117 | 0.030 |
Why?
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 238 | 0.030 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2016 | 1879 | 0.030 |
Why?
| DNA Copy Number Variations | 1 | 2016 | 154 | 0.030 |
Why?
| Protein Domains | 1 | 2016 | 207 | 0.030 |
Why?
| Gene Knockdown Techniques | 1 | 2016 | 299 | 0.030 |
Why?
| Interdisciplinary Communication | 1 | 2016 | 183 | 0.030 |
Why?
| Sequence Analysis, DNA | 2 | 2008 | 723 | 0.030 |
Why?
| Exome | 1 | 2016 | 200 | 0.030 |
Why?
| Chromosome Mapping | 1 | 2016 | 487 | 0.030 |
Why?
| rhoC GTP-Binding Protein | 1 | 2014 | 5 | 0.030 |
Why?
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2014 | 5 | 0.030 |
Why?
| Urothelium | 1 | 2015 | 33 | 0.030 |
Why?
| Metabolomics | 1 | 2019 | 521 | 0.030 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2020 | 959 | 0.030 |
Why?
| Survival Analysis | 1 | 2017 | 1211 | 0.030 |
Why?
| rac1 GTP-Binding Protein | 1 | 2014 | 56 | 0.030 |
Why?
| Gene Expression | 1 | 2019 | 1421 | 0.030 |
Why?
| Neoplasm Transplantation | 1 | 2014 | 228 | 0.030 |
Why?
| Gene Expression Regulation | 1 | 2023 | 2319 | 0.030 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 329 | 0.030 |
Why?
| Molecular Sequence Data | 2 | 2009 | 2785 | 0.030 |
Why?
| Sequence Analysis, Protein | 1 | 2014 | 27 | 0.030 |
Why?
| Neoplasm Grading | 1 | 2015 | 242 | 0.030 |
Why?
| Intrinsically Disordered Proteins | 1 | 2014 | 15 | 0.030 |
Why?
| Eflornithine | 1 | 2013 | 3 | 0.030 |
Why?
| Ornithine Decarboxylase | 1 | 2013 | 9 | 0.030 |
Why?
| Point Mutation | 1 | 2015 | 216 | 0.030 |
Why?
| Follistatin | 1 | 2013 | 12 | 0.030 |
Why?
| Protein Conformation | 1 | 2016 | 805 | 0.030 |
Why?
| Amino Acid Motifs | 1 | 2014 | 197 | 0.030 |
Why?
| Aminoglycosides | 1 | 2013 | 13 | 0.030 |
Why?
| Blotting, Western | 1 | 2016 | 1147 | 0.030 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2016 | 358 | 0.030 |
Why?
| Databases, Factual | 1 | 2018 | 1125 | 0.030 |
Why?
| Polymerase Chain Reaction | 1 | 2016 | 993 | 0.030 |
Why?
| Area Under Curve | 1 | 2014 | 274 | 0.030 |
Why?
| Treatment Outcome | 2 | 2017 | 9087 | 0.030 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 439 | 0.030 |
Why?
| Clinical Trials as Topic | 1 | 2017 | 931 | 0.030 |
Why?
| beta-Lactams | 1 | 2013 | 27 | 0.030 |
Why?
| Neoplasm Staging | 1 | 2016 | 1167 | 0.030 |
Why?
| Enzyme Activation | 1 | 2015 | 785 | 0.030 |
Why?
| Organ Size | 1 | 2013 | 434 | 0.030 |
Why?
| Doxycycline | 1 | 2012 | 55 | 0.030 |
Why?
| Genes, ras | 1 | 2012 | 91 | 0.030 |
Why?
| Bone Marrow Transplantation | 1 | 2013 | 239 | 0.030 |
Why?
| Cell Cycle Checkpoints | 1 | 2012 | 84 | 0.030 |
Why?
| Antigens, CD | 1 | 2014 | 442 | 0.020 |
Why?
| Young Adult | 2 | 2017 | 10465 | 0.020 |
Why?
| Quinolones | 1 | 2013 | 97 | 0.020 |
Why?
| Cytokines | 1 | 2019 | 1840 | 0.020 |
Why?
| Hydrogen Peroxide | 1 | 2013 | 288 | 0.020 |
Why?
| Middle Aged | 3 | 2017 | 26732 | 0.020 |
Why?
| Linear Models | 1 | 2014 | 768 | 0.020 |
Why?
| Repressor Proteins | 1 | 2014 | 366 | 0.020 |
Why?
| Benzimidazoles | 1 | 2012 | 138 | 0.020 |
Why?
| DNA | 1 | 2017 | 1352 | 0.020 |
Why?
| Adenosine Triphosphate | 1 | 2013 | 430 | 0.020 |
Why?
| Recombinant Proteins | 1 | 2013 | 1230 | 0.020 |
Why?
| Pupa | 1 | 2009 | 10 | 0.020 |
Why?
| Body Weight | 1 | 2013 | 870 | 0.020 |
Why?
| Gene Library | 1 | 2009 | 114 | 0.020 |
Why?
| Cell Survival | 1 | 2012 | 1020 | 0.020 |
Why?
| Adolescent | 2 | 2017 | 17837 | 0.020 |
Why?
| Immunohistochemistry | 1 | 2013 | 1629 | 0.020 |
Why?
| Larva | 1 | 2009 | 194 | 0.020 |
Why?
| Staphylococcus aureus | 1 | 2012 | 389 | 0.020 |
Why?
| Escherichia coli | 1 | 2012 | 720 | 0.020 |
Why?
| Mice, Transgenic | 1 | 2013 | 1947 | 0.020 |
Why?
| Disease Progression | 1 | 2015 | 2380 | 0.020 |
Why?
| Synteny | 1 | 2007 | 17 | 0.020 |
Why?
| Gene Order | 1 | 2007 | 24 | 0.020 |
Why?
| Risk Factors | 1 | 2021 | 8631 | 0.020 |
Why?
| Genome, Mitochondrial | 1 | 2007 | 27 | 0.020 |
Why?
| RNA, Messenger | 1 | 2015 | 2552 | 0.020 |
Why?
| Codon | 1 | 2007 | 86 | 0.020 |
Why?
| Time Factors | 1 | 2017 | 6115 | 0.020 |
Why?
| DNA Transposable Elements | 1 | 2007 | 101 | 0.020 |
Why?
| Sequence Alignment | 1 | 2007 | 323 | 0.020 |
Why?
| Immunity | 1 | 2007 | 121 | 0.020 |
Why?
| Multigene Family | 1 | 2007 | 190 | 0.020 |
Why?
| Terminology as Topic | 1 | 2008 | 187 | 0.020 |
Why?
| Aged, 80 and over | 1 | 2017 | 6345 | 0.020 |
Why?
| RNA, Untranslated | 1 | 2007 | 113 | 0.020 |
Why?
| Reproduction | 1 | 2007 | 178 | 0.020 |
Why?
| Drosophila Proteins | 1 | 2007 | 164 | 0.020 |
Why?
| Muscle, Skeletal | 1 | 2013 | 1472 | 0.010 |
Why?
| Child | 1 | 2023 | 18407 | 0.010 |
Why?
| RNA | 1 | 2008 | 809 | 0.010 |
Why?
| Disease Models, Animal | 1 | 2008 | 3531 | 0.010 |
Why?
|
|
Costello's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|